• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Milestone Scientific Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    1/13/25 4:51:36 PM ET
    $MLSS
    Industrial Specialties
    Health Care
    Get the next $MLSS alert in real time by email
    mlss20250113_8k.htm
    false 0000855683 0000855683 2025-01-12 2025-01-12
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     
    FORM 8-K
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): January 12, 2025
     
     
    MILESTONE SCIENTIFIC INC.
    (Exact Name of Registrant as Specified in Its Charter)
     
     
    Delaware
     
    001-14053
     
    13-3545623
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission File Number)
     
    (I.R.S. Employer
    Identification Number)
     
    425 Eagle Rock Avenue
    Suite 403
    Roseland, NJ 07068
    (Address of principal executive offices)
     
    973-535-2717
    (Registrant’s telephone number, including area code)
     
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name on exchange on which registered
    Common Stock
    MLSS
    NYSE American
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    On January 12, 2025, Mr. Giandomenico Trombetta, a director of Milestone Scientific Inc. (the “Company”), advised the Chairman of the Board that he is resigning, effective immediately, as a director.
     
    Mr. Trombetta indicated that his resignation is for personal reasons and the need to attended to other matters of an immediate nature that leave him unable to fulfill his responsibilities as a member of the board of the Company.
     
    Mr. Trombetta indicated that his decision to leave the board of directors was not the result of any disagreements with the Company or the board of directors as to any matter relating to the Company’s operations, finances, policies, or practices.
     
    Item 9.01 Financial Statements and Exhibits
     
    (d)
    Exhibits
     
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     
     
     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    MILESTONE SCIENTIFIC INC.
       
    Dated: January 13, 2025
    /s/ Neal Goldman
     
    Neal Goldman,
     
    Acting Chief Executive Officer
     
     
    Get the next $MLSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MLSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2025

      ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial results for the first quarter ended March 31, 2025. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, commented, "We are encouraged by the growing momentum in our medical segment, where first quarter results reflect increased traction for the CompuFlo® Epidural System. During the quarter, we were pleased to see new practices integrating CompuFlo into their workflows. These adoptions reflect both the clinical

      5/15/25 4:15:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Reports Year-End 2024 Financial Results and Reports Strong Outlook for 2025

      Reports expansion of CompuFlo® Epidural System across additional pain management clinics and ambulatory surgery centers following Medicare price assignment in multiple U.S. states ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) --  Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2024. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, "While 2024 was a year of transition for Milestone Scientific, we laid the foundation for a strong rebound in 2025. We foc

      4/15/25 4:10:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Expands CompuFlo® Epidural System Footprint with InfiniSurg, LLC in New Jersey

      ROSELAND, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that InfiniSurg, LLC, a premier ambulatory surgery center based in New Jersey, has incorporated the CompuFlo® Epidural System into its clinical practice. The device will be utilized by Roman Kosiborod, DO, a highly experienced anesthesiologist and pain management physician. This order was received through Milestone's distributor, Axial Biologics. Dr. Kosiborod brings over two decades of expertise in interventional pain management and ambulatory anesthesia. He is the Managing Dir

      4/1/25 8:30:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Financials

    Live finance-specific insights

    See more
    • Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024

      Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported financial results for the third quarter ended September 30, 2024. Arjan Haverhals, CEO of Milestone Scientific, commented, "We are pleased to report a 22% year-over-year increase in total revenue, reaching $2.5 million for t

      11/14/24 4:30:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Schedules Third Quarter 2024 Financial Results and Business Update Conference Call

      ROSELAND, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 15th, 2024, to discuss the company's financial results for the third quarter ended September 30, 2024, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 169295. A webcast and replay of the call may be acc

      11/12/24 8:30:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Provides Business Update and Reports Financial Results for the Second Quarter of 2024

      Secured Medicare price assignment for the CompuFlo® Epidural System in multiple U.S. states Gross margin for the second quarter of 2024 increased to 76.1% from 65.0% for the same period last year driven by an increase in U.S. e-commerce sales ROSELAND, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2024. Arjan Haverhals, CEO and President of Milestone Scientific, commented, "We are successfully advancing our reimbursement strategy for the CompuFlo®

      8/15/24 7:00:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Milestone Scientific Inc.

      10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      5/15/25 4:01:13 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      4/22/25 4:10:54 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • SEC Form 10-K filed by Milestone Scientific Inc.

      10-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      4/15/25 4:01:07 PM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Leadership Updates

    Live Leadership Updates

    See more
    • Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO

      ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition. Mr. Haverhals' retirement, following a distinguished career of over 30 years in the medical device and pharmaceutical industries, reflects his desire to spend more ti

      11/14/24 4:00:00 PM ET
      $CTHR
      $MLSS
      Consumer Specialties
      Consumer Discretionary
      Industrial Specialties
      Health Care
    • Milestone Scientific Appoints Pain Management Industry Veteran Dr. Didier Demesmin to its Board of Directors

      ROSELAND, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dr. Didier Demesmin, MD, MBA, to the Board of Directors. Dr. Demesmin is an interventional pain medicine physician who is double board-certified in both anesthesiology and pain medicine. He is the founder of University Pain and Spine center, a well-respected interventional pain management and spine surgery clinic that operates 7 offices across New Jersey and New York. He is also the founder of STEMMEE Surgery Center, an ambulatory surgery center providing st

      9/12/23 11:00:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Announces Distribution Agreement with Leading European Dental Distributor & Manufacturer Sweden & Martina

      ROSELAND, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provides painless and precise injections, today announced it has entered into a distribution agreement with Sweden & Martina, a leading European dental distributor and manufacturer. Under the agreement, Sweden & Martina has been awarded the exclusive rights to market Milestone's STA Single Tooth Anesthesia System® (STA) in the new markets of Spain, Portugal and France. In addition, Sweden & Martina will replace the Company's current distributor in Italy and become its exclusive STA distributor in this market. Founded in 1972, Sweden &

      1/12/23 8:30:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcgeehan Michael sold $15,532 worth of shares (20,000 units at $0.78), decreasing direct ownership by 3% to 575,273 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      12/20/24 4:00:59 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Director Osser Leonard sold $100,425 worth of shares (107,984 units at $0.93), decreasing direct ownership by 2% to 4,606,882 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      10/23/24 4:55:21 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Director Mcgeehan Michael sold $209 worth of shares (209 units at $1.00), decreasing direct ownership by 0.04% to 595,273 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      9/27/24 9:12:50 AM ET
      $MLSS
      Industrial Specialties
      Health Care